Vosoritide vs Navepegritide
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two drugs for achondroplasia, a form of dwarfism, that copy a growth signal called CNP. One is daily and one is weekly, and both are FDA approved. Both were approved on how fast children grew, not on final adult height. Adult height is what families most want to know, and neither trial could measure it.
- Vosoritide people
- 0
- Vosoritide nulls
- 0
- Navepegritide people
- 0
- Navepegritide nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as Voxzogo to help children with achondroplasia, a form of dwarfism, grow taller while their growth plates are still open. The approval rests on how fast they grew, not on their final adult height.
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
VosoritideVosoritide (Voxzogo), C-type natriuretic peptide analogue
Approved for achondroplasia, a genetic cause of short height, on a final-stage trial. Children grew about 1.6 cm more a year. Nobody knows yet whether they end up taller as adults.
Column B
NavepegritideNavepegritide (TransCon CNP, Yuviwel)
A weekly shot that slowly releases C-type natriuretic peptide, or CNP. The FDA approved it in February 2026 for achondroplasia in children aged two and older.
Side by side, on the facts we can check
| What we compare | Vosoritide | Navepegritide |
|---|---|---|
| Category | Growth Hormone | Hormone |
| FDA status | FDA-approved as Voxzogo to help children with achondroplasia, a form of dwarfism, grow taller while their growth plates are still open. The approval rests on how fast they grew, not on their final adult height. | FDA-approved in 2026 for achondroplasia, the most common form of dwarfism. It was an early, conditional (accelerated) approval |
| Half-life | Roughly 20 to 30 minutes, very short, which is why it requires daily subcutaneous injection despite being engineered for stability against neutral endopeptidase. | Weekly dosing (prodrug release) |
| Molecular weight | Roughly 4.1 kDa. A 39-amino-acid peptide. | No single molecular weight: a CNP peptide conjugated to a PEG carrier of indefinite length (KEGG lists the peptide plus an indefinite PEG term) |
| How it works | Vosoritide is a 39 amino acid copy of C-type natriuretic peptide (CNP). It is changed so an enzyme that normally destroys CNP within minutes (neutral endopeptidase) cannot break it down as easily. It binds a receptor called NPR-B. That raises a messenger inside the cell (cyclic GMP) and switches on an enzyme (protein kinase G), which blocks a growth-braking chain of signals (RAF, MEK and ERK) at an early link. In achondroplasia, the faulty FGFR3 gene drives that same chain too hard, and growth plate cells stop multiplying. So vosoritide brakes the pathway the gene fault speeds up. It pushes back further down the line. It does not fix the fault itself. | It is a slow-release form of CNP. It switches on the NPR-B receptor, which turns down the MAPK signal driven by FGFR3 in the growth plates of bones. |
| Studies in people | 1 | 2 |
| Evidence | Limited: 1 completed trial, none stating how many people | Preliminary: 2 human studies where nobody was given it |
| Legal status, US | FDA-approved, prescription only | FDA-approved (achondroplasia), prescription only |
Frequently asked questions
What is the difference between Vosoritide and Navepegritide?
Vosoritide: Approved for achondroplasia, a genetic cause of short height, on a final-stage trial. Children grew about 1.6 cm more a year. Nobody knows yet whether they end up taller as adults. Navepegritide: A weekly shot that slowly releases C-type natriuretic peptide, or CNP. The FDA approved it in February 2026 for achondroplasia in children aged two and older.
Which has stronger research evidence, Vosoritide or Navepegritide?
Each compound gets a band worked out from facts we counted, with the math shown. Vosoritide is Limited (1 completed trial, none stating how many people). Navepegritide is Preliminary (2 human studies where nobody was given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Vosoritide and Navepegritide FDA-approved?
Vosoritide: FDA-approved as Voxzogo to help children with achondroplasia, a form of dwarfism, grow taller while their growth plates are still open. The approval rests on how fast they grew, not on their final adult height.. Navepegritide: FDA-approved in 2026 for achondroplasia, the most common form of dwarfism. It was an early, conditional (accelerated) approval.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.